Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet succeeds Rice Powell as CEO of the Management Board of Fresenius Medical Care

·3-min read

Fresenius Medical Care AG & Co. KGaA / Key word(s): Personnel
Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet succeeds Rice Powell as CEO of the Management Board of Fresenius Medical Care

03-May-2022 / 22:12 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

In today’s meeting the Supervisory Board of Fresenius Medical Care's General Partner unanimously appointed Dr. Carla Kriwet as CEO of the Management Board effective January 1, 2023. Dr. Carla Kriwet succeeds Rice Powell, who will step down from the Management Board in light of the age limit for members of the Management Board when his contract expires at the end of December 2022.

In her capacity as CEO of Fresenius Medical Care, Dr. Carla Kriwet will also be a member of the Management Board of Fresenius Management SE.

Person making the notification:
Dr. Dominik Heger
EVP & Head of Investor Relations, Strategic Development & Communications
P. +49 6172 609 2601

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,171 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company’s website at

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

03-May-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at




Fresenius Medical Care AG & Co. KGaA

Else-Kröner-Straße 1

61352 Bad Homburg



+49 (0) 6172- 609 2525


+49 (0) 6172- 609 2301










Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange

EQS News ID:



End of Announcement

DGAP News Service

show this
show this